| 姚灯礼,杨华,罗芳,等.经直肠超声造影联合血清微 RNA-130b-3p、磷酸葡萄糖变位酶样蛋白 5对早期前列腺癌的诊断价值[J].安徽医药,2025,29(5):972-976. |
| 经直肠超声造影联合血清微 RNA-130b-3p、磷酸葡萄糖变位酶样蛋白 5对早期前列腺癌的诊断价值 |
| Diagnostic value of transrectal contrast-enhanced ultrasound combined with serum miR-130b-3p and PGM5 in early prostate cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2025.05.023 |
| 中文关键词: 前列腺肿瘤 经直肠超声造影 微 RNA-130b-3p 磷酸葡萄糖变位酶样蛋白 5 诊断 |
| 英文关键词: Prostatic neoplasms Transrectal contrast-enhanced ultrasound Micro RNA-130b-3p Phosphoglucose mutase like protein 5 Diagnosis |
| 基金项目: |
|
| 摘要点击次数: 61 |
| 全文下载次数: 29 |
| 中文摘要: |
| 目的观察早期前列腺癌病人血清微 RNA-130b-3p(miR-130b-3p)、磷酸葡萄糖变位酶样蛋白 5(PGM5)和经直肠超声造影参数的变化，探讨三者联合对早期前列腺癌的鉴别诊断价值。方法选取 2022年 5月至 2023年 7月铜仁市人民医院 138例早期前列腺癌病人为前列腺癌组， 145例前列腺良性增生病人为良性增生组，均进行经直肠超声造影检查，并采用实时荧光定量逆转录聚合酶链式反应(qRT-PCR)检测血清 miR-130b-3p水平，酶联免疫吸附试验(ELISA)检测 PGM5水平。各指标绘制受试者操作特征曲线( ROC曲线)分析早期前列腺癌诊断价值，曲线下面积( AUC)行 Z检验；与病理结果的一致性采用 Kappa一致性检验。结果前列腺癌组血清 miR-130b-3p水平 1.32±0.35及超声造影参数中梯度( 1.76±0.43)dB/s、峰值强度( 15.27±0.64)dB显著高于良性增生组［1.02±0.24、(1.35±0.34)dB/s、(14.35±0.27)dB］血清 PGM5(3.35±0.71)μg/L显著低于良性增生组(4.24±1.06)μg/L(P<0.05)。经直肠超声造影、 miR-130b-3p、PGM5单独及鉴别诊断早期前列腺癌的 AUC分别为 0.86、联合，0.80、0.81、0.93，联合 AUC高于单独 AUC(P<0.05)。经直肠超声造影单独及联合血清指标检查结果与病理结果的 Kappa一致性系数分别为 0.73、0.81(P<0.05)。经直肠超声造影、 miR-130b-3p、PGM5联合鉴别诊断早期前列腺癌的灵敏度、阴性预测值显著高于各自单独诊断，准确度高于血清 miR-130b-3p、PGM5单独诊断( P<0.05)。结论经直肠超声造影联合血清 miR-130b-3p、PGM5诊断早期前列腺癌的灵敏度、阴性预测值较高，且与病理结果的一致性最高。 |
| 英文摘要: |
| Objective To observe the changes in serum microRNA-130b-3p (miR-130b-3p), phosphoglucose mutase like protein 5 (PGM5), and transrectal contrast-enhanced ultrasound parameters in patients with early prostate cancer, and to explore the combinedvalue of the three in the differential diagnosis of early prostate cancer.Methods A total of 138 early stage prostate cancer patients inthe People's Hospital of Tongren from May 2022 to July 2023 were selected as the prostate cancer group, and 145 patients with benignprostatic hyperplasia were selected as the benign prostatic hyperplasia group. Transrectal contrast-enhanced ultrasound was performed on the patients, and serum miR-130b-3p level was measured using qRT-PCR, and the PGM5 level was measured using enzyme-linked immunosorbent assay (ELISA). ROC curve was plotted to analyze the diagnostic value of various indicators for early prostate cancer,and the AUC was subjected to a Z-test; the consistency with the pathological results was tested using Kappa consistency test.Results The serum miR-130b-3p 1.32±0.35 level and the gradient (1.76±0.43) dB/s and peak intensity (15.27±0.64)dB of contrast-enhanced ul-trasound parameters in the prostate cancer group were obviously higher than those in the benign hyperplasia group [1.02±0.24, ( 1.35±0.34)dB/s, (14.35±0.27)dB, while serum PGM5 (3.35±0.71)μg/L was obviously lower than that in the benign hyperplasia group (4.24±1.06)μg/L (P<0.05). The AUC for differential diagnosis of early prostate cancer using transrectal contrast-enhanced ultrasound,miR-130b-3p, and PGM5 alone and in combination was 0.86, 0.80, 0.81, and 0.93, respectively, the combined AUC was higher than the sin-gle AUC (P<0.05). The Kappa consistency coefficients between the results of transrectal contrast-enhanced ultrasound single and it combined serum indicators with pathological results were 0.73 and 0.81, respectively (P<0.05). The sensitivity and negative predictive value of combined transrectal contrast-enhanced ultrasound, miR-130b-3p, and PGM5 in the differential diagnosis of early prostate can-cer were obviously higher than those of individual diagnoses, the accuracy was higher than that of serum miR-130b-3p and PGM5 alone diagnosis (P<0.05).Conclusion Transrectal contrast-enhanced ultrasound combined with serum miR-130b-3p and PGM5 has a high-er sensitivity, negative predictive value, and highest consistency with pathological results in the diagnosis of early prostate cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
